Oral Cerebrolysin® enhances brain alpha activity and improves cognitive performance in elderly control subjects

Journal of Neural Transmission, Supplement

Volumn , Issue 59, 2000, Pages 315-328

  Álvarez, X Antón ^a   Lombardi, V R M ^a   Corzo, L ^a   Perez P ^a   Pichel, V ^a   Laredo, M ^a   Hernandez A ^a   Freixeiro, F ^a   Sampedro, C ^a   Lorenzo, R ^a   Alcaraz, M ^a   Windisch, M ^b   Cacabelos, R ^b  

^a Centro de Investigacion Biomedica EuroEspes   (Spain)

^b JSW Life Sciences GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBROLYSIN; NOOTROPIC AGENT; AMINO ACID;

ADULT; AGED; ALPHA RHYTHM; ARTICLE; ATTENTION; BIOENERGY; BRAIN; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELTA RHYTHM; DOSE TIME EFFECT RELATION; ELECTRODE; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MEMORY; NORMAL HUMAN; OCCIPITAL LOBE; PRIORITY JOURNAL; RECALL; RECOGNITION; AGING; DRUG EFFECT; ELECTROCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; HEART RATE; HEMODYNAMICS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; REFERENCE VALUE;

ADMINISTRATION, ORAL; AGED; AGING; ALPHA RHYTHM; AMINO ACIDS; BRAIN; COGNITION; ELECTROCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; FEMALE; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; REFERENCE VALUES;

EID: 0033624434     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6781-6_33     Document Type: Article

References (25)

1. Albrecht E, Hingel S, Crailsheim K, Windisch M (1993) The effects of cerebrolysin on survival and sprouting of neurons from cerebral hemispheres and from the brainstem of chick embryos in vitro. Adv Biosci 87: 341-342
2. Álvarez XA, Franco A, Fernández-Novoa L, Cacabelos R (1996) Blood levels of histamine, IL-1β and TNF-alpha in patients with mild to moderate Alzheimer's disease. Mol Chem Neuropathol 29: 237-252
3. Álvarez XA, Miguel-Hidalgo JJ, Fernändez-Novoa L, Díaz J, Sempere JM, Cacabelos R (1997a) Anapsos: Neuroimmunotrophic treatment in Alzheimer disease and neurodegenerative disorders. CNS Drug Rev 3: 181-206
4. Álvarez XA, Laredo M, Corzo D, Fernández-Novoa L, Mouzo R, Perea JE, Daniele D, Cacabelos R (1997b) Citicoline improves memory in elderly subjects. Meth Find Exp Clin Pharmacol 19: 201-210
5. Álvarez XA, Fernández-Novoa L, Sampedro C, Lombard V, Windisch M, Cacabelos R (1999a) Neuroimmunotrophic effects of Cerebrolysin® in an animal model of hipocampal degeneration induced by β-Amyloid, In: Korczyn AD (ed) Vascular dementia. Monduzzi Editore, Bologna, pp 233-237
6. Álvarez XA, Mouzo R, Pichel V, Perez P, Laredo M, Fernández-Novoa L, Corzo L, Zas R, Alcaraz M, Secades JJ, Lozano R, Cacabelos R (1999b) Effects of CDP-choline on cognitive performance, brain bioelectrical activity and brain hemodynamics in Alzheimer's disease patients: a double-blind placebo controlled study. Ann Psychiatry 7: 331-352
7. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders. 4th edn (DSM-IV), APA, Washington
8. Cacabelos R, Caamaño J, Vinagre D, Lao JI, Beyer K, Álvarez XA (1996) Brain mapping and transcranial Doppler ultrasonography in Alzheimer Drug monitoring; In: Becker R, Giacobini E (eds) Alzheimer disease: From molecular biology to therapy. Birkhäuser, Boston, pp 469-473
9. Franco-Maside A, Vinagre D, Caamaño J, Álvarez XA, Fernández-Novoa L, Novo B, Zas R, Gómez MJ, Cacabelos R (1995) Brain mapping in neurogeriatrics. Neurogerontol Neurogeriatr 1: 119-139
10. Funke M, Fiehler J, Mewes I, Eiselt M, Rother I, Windisch M (1998) Dose-dependent effects of Cerebrolysin on EEG and Short term memory in healthy volunteers during control and hyperventilation induced cerebral ischemia. J Neural Transm [Suppl 53]: 385-398
11. Hutter-Paier B, Grygar E, Windisch M (1996a) Death of cultured telencephalon neurons induced by glutamate is reduced by the peptide derivative cerebrolysin. J Neural Transm 47: 267-273
12. Hutter-Paier B, Frühwirth M, Windisch M (1996b) Ischemia induced loss of map2 is prevented by cerebrolysin and THA. Mol Biol Cell 7: 1278
13. Hutter-Paier B, Steiner E, Windisch M (1998a) Cerebrolysin protects isolated neurons from neurodegeneration after brief histotoxic hypoxia. J Neural Transm [Suppl 53]: 351-361
14. Hutter-Paier B, Grygar E, Fruhwirth M, Temmenl I, Windisch M (1998b) Further evidence that Cerebrolysin protects cortical neurons from neurodegeneration in vitro. J Neural Transm [Suppl 53]: 363-372
15. Lombardi VRM, Windisch M, García M, Cacabelos R (1999) Effects of Cerebrolysin® on in vitro primary microglial and astrocyte rat cell cultures. Meth Find Exp Pharmacol 21: 331-338
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of NINCDS-ADRDA Work Group. Neurology 34: 939-944
17. Overall JE, Schaltenbrand R (1992) The SKT neuropsychological test battery. J Geriatr Psychiatry Neurol 5: 220-227
18. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141: 1356-1364
19. Rüther E, Ritter R, Apecechea M, Freytag S, Windisch M (1994) Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 27: 32-40
20. Saletu B, Paulus E, Linzmayer L, et al. (1995) Nicergoline in senile dementia of the Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology 117: 385-395
21. Saletu B, Grünberger J, Anderer P, Linzmayer E (1996a) Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: I. Double-blind, placebo-controlled EEG mapping and psychometric studies under normoxia. Meth Find Exp Clin Pharmacol 18: 55-66
22. Saletu B, Grünberger J, Anderer P, Linzmayer E (1996b) Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: II. Double-blind, placebo-controlled EEG mapping and psychometric studies under hypoxia. Meth Find Exp Clin Pharmacol 18: 67-81
23. Satou T, Imano M, Akai F, Hashimoto S, Itoh T, Fujimoto M (1993) Morphological observation of effects of cerebrolysin on cultured neural cells. Adv Biosci 87: 195-196
24. Schwab M, Antonow-Schlorke I, Zwiener U, Bauer R (1998) Brain-derived peptides reduce size of cerebral infarction and loss of MAP2 immunoreactivity after local ischemia in rats. J Neural Transm [Suppl 53]: 299-311
25. Windisch M, Gschanes A, Hutter-Paier B (1998) Neurotrophic activities and therapeutic experience with a brain derived peptide preparation. J Neural Transm [Suppl 53]: 289-298